Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berotralstat (BCX7353) for HAE Attack Prevention
NCT02870972Phase 2Completed
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Aug 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of berotralstat in hereditary angioedema (HAE), sponsored by BioCryst Pharmaceuticals, Inc.. Started Aug 2016; status: completed.
02
Drugs
berotralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT02870972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02870972.